吉西他滨联合顺铂对晚期非小细胞肺癌的临床疗效观察  

Clinical Observation of Gemcitabine Combined with Cisplatin in the Treatment of Advanced Non-small Cell Lung Cancer

作　　者：芮晓艳[1] 孙沫[1] 丁婷婷[1] 张艳喜[1] 范洪峰[1] RUI Xiaoyan;SUN Mo;DING Tingting(The First People＇s Hospital of Chuzhou,Chuzhou,23900)

机构地区：[1]安徽省滁州市第一人民医院,239000

出　　处：《实用癌症杂志》2018年第5期811-813,共3页The Practical Journal of Cancer

摘　　要：目的观察吉西他滨联合顺铂对晚期非小细胞肺癌的临床疗效。方法回顾性分析91例晚期非小细胞肺癌患者的临床资料,随机分为对照组(45例)和观察组(46例),分别给予多西他赛联合顺铂和吉西他滨联合顺铂治疗。观察两组的治疗效果、无进展生存时间、不良反应发生情况,并进行比较。结果观察组总缓解率为45.65%,高于对照组的44.44%,但经比较差异无统计学意义(P>0.05);观察组和对照组无进展生存时间分别为(5.45±1.03)个月和(5.13±1.05)个月,差异无统计学意义(P>0.05);两组患者治疗过程中均出现一定的不良反应,包括血小板降低和白细胞降低等,其中除血小板降低发生率外(P<0.05),两组各项不良反应发生率经比较均无统计学意义。结论对晚期非小细胞肺癌采用吉西他滨联合顺铂化疗可以获得一定的临床疗效,具有一定的应用可行性。Objective To observe the clinical efficacy of gemcitabine combined with cisplatin in the treatment of advanced non-small cell lung cancer. Methods Review the clinical data of patients with non small cell lung cancer were analyzed retrospectively in 91 cases of advanced in our hospital in December 2013 ~ 2015 year in October,were randomly divided into control group（45 cases） and observation group（46 cases）,were given docetaxel combined with cisplatin and gemcitabine combined with cisplatin in the treatment of. The therapeutic effect,progression free survival time and adverse reactions were observed and compared between the two groups. Results The effect of two groups of patients were deter mined and compared to the total remission rate of observation group was 45. 65%,higher than 44. 44% in the control group,but there was no significant difference,（ P〈0. 05）;the progression free survival time statistics,observation group and control group respectively（5. 45 ± 1. 03） and（5. 13± 1. 05） months,there was no significant difference,（ P〉0. 05）;some adverse reactions were found in the two groups during treatment,including thrombocytopenia and leukopenia,which reduce the incidence rate of platelet in the observation group was significantly lower than the control group,the difference was statistically significant.（ P〈0. 05）,but the incidence of adverse reactions after there were no statistical differences（ P〉0. 05）. Conclusion Conclusion gemcitabine combined with cisplatin in the treatment of advanced non-small cell lung cancer has a certain clinical efficacy,and has certain application feasibility.

关 键 词：非小细胞肺癌 晚期 吉西他滨 顺铂 临床疗效 

分 类 号：R734.2[医药卫生—肿瘤]